PLAT-08: SC-DARIC33 for Relapsed or Refractory CD33+ AML
This study is testing a new type of immunotherapy called SC-DARIC33 for children and young adults (up to age 30) with acute myeloid leukemia (AML) that has come back or hasn't responded to previous treatments. This includes those who have had a stem cell transplant. SC-DARIC33 is made from your own immune cells, which are specially modified to fight your leukemia. The main goals are to see how safe SC-DARIC33 is and if it can be successfully made for each patient. Your leukemia must have a specific marker called CD33 to be eligible. The study plans to enroll 18 participants.
- Study design
- This is a Phase 1, open-label study, meaning both you and your doctors will know what treatment you are receiving. It is not randomized, and it plans to enroll 18 participants.
- What's involved
- You would receive an infusion of SC-DARIC33, followed by taking rapamycin by mouth intermittently. The study will assess side effects and manufacturing success for 28 days after the infusion.
- Compensation
- Not stated in the trial record.
- Follow-up
- The study will assess adverse events and manufacturing success for 28 days after the infusion.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
PLAT-08: A Study Of SC-DARIC33 CAR T Cells In Pediatric And Young Adults With Relapsed Or Refractory CD33+ AML
At a glance
Conditions
Where it's being run
1 sites across 1 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Adverse events associated with SC-DARIC33 cell product infusions will be assessed28 days post-infusion
The type, frequency, severity, and duration of adverse events will be summarized
- Ability to successfully manufacture SC-DARIC3328 days
Measure of the number of successfully manufactured SC-DARIC33 products